PTO/SB/08a (08-03 )
Approved for use through 97/31/2006, ONB 0651-0201
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10567195		
Filing Date				
First Named Inventor Lynd		on Higgins		
Art Unit				
Examiner Name				
Attorney Docket Number		ABAC 0101 PUSA	_	

	Remove									
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup> Issue Date Name of Patentee or Applie of cited Document		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	5660288	A	1997-08-26 Nyman, Jr.						
	2	4458821	A							
	3	5950850	A							
	4	4903865	A1							
	5	6148996	A1							
	6	6230684	B1	2001-05-15	Fredrick Michael Coory					
If you wis	h to a	dd additional U.S. Paten	rt citatio	ı n information pl	ease click the Add button.	Add				
	U.S.PATENT APPLICATION PUBLICATIONS Remove									
Examiner Initial*	Examiner Cite No Publication Number Kind Date Name of Patentee or Applicant Relevant Figures									

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10567195
Filing Date		
First Named Inventor Lynd		on Higgins
Art Unit		
Examiner Name		
Attorney Docket Number		ARAC 0101 PUSA

	1	2003001	15490	A1	2003-0	1-23	Taha					
If you wis	h to a	dd additio	nal U.S. Publis	shed Ap	plication	citation	n information p	oleas	e click the Ad	d butto	n. Add	_
					FOREIG	SN PAT	ENT DOCUM	ENT	'S		Remove	_
Examiner Initial*	Cite No	Foreign Number	Document 3	Country Code <sup>2</sup>			Publication Date	App	Applicant of cited		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т5
	1	1110009	93	JP		A	1999-04-13		Shibazaki Seisakusho KK			
	2	0809140	02	JP		A	1996-04-09		Shibazaki Seisakusho KK			
	3	1105979	91	JP	P A		1999-03-02	Shi	bazaki Seisaku	sho		
If you wish	h to a	dd additio	nal Foreign Pa	atent Do	cument	citation	information pl	lease	click the Add	button	Add	
				NON	I-PATE	NT LITE	RATURE DO	CUM	IENTS		Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Тs			
	1											
If you wis	h to a	dd additio	onal non-patent	t literatu	re docu	ment cit	ation informat	ion p	lease click the	Add b	utton Add	
					EX	AMINE	R SIGNATUR	Ε				
Examiner	Examiner Signature Date Considered											

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

Application Number		10567195	
Filing Date			
First Named Inventor Lyndon		on Higgins	
Art Unit			
Examiner Name			
Attorney Docket Numb	er	ABAC 0101 PUSA	
	Filing Date First Named Inventor Art Unit Examiner Name	Filing Date First Named Inventor Lynd Art Unit	

See for Codes of USPTO Palent Documents at your USPTO CAP and FEP P010.4. Easter office in all research in documents, by the lost-left crode (WPO) Standard ST3,3 \*\*PC Legamene gainted connectine, the industries of the year of the region of the Engeneer mater industries the search received for the palent document.

\*\*Indicate Courterful by the appropriate symbols as indicated on the document under WPO Standard ST,16 if possible. \*\*Applicant is to place a check mark here if frequire interquent extractions a statistical or stati

# Application Number 1056/195 Filing Date Fi

### CERTIFICATION STATEMENT

m.	-	000		 	 appropriate	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/John E. Nemazı/	Date (YYYY-MM-DD)	2006-06-21
Name/Print	John E. Nemazi	Registration Number	30876

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenian's (Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.32.11-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.211-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.